A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes

Inclusion Criteria:

• Participants must have at screening:

1. Body mass index (BMI) greater than or equal to (≥)30.0 kg/m^2; or

2. BMI ≥27.0 kg/m^2 and <30.0 kg/m^2 with at least one weight-related comorbidity,such as prediabetes, hypertension, dyslipidemia, diagnosis of obstructive sleepapnea, or weight-related cardiovascular disease

• History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight

• Ability and willingness to self-administer the study drug (or receive an injectionfrom a trained individual if visually impaired or with physical limitations)

Exclusion Criteria:

• History of Type 1 diabetes mellitus (T1DM) or T2DM, or history of ketoacidosis orhyperosmolar state/coma. Prior, but not current, diagnosis of gestational diabetesis allowed if no history of diabetes is recorded since.

• Self-reported change in body weight >5 kg within 3 months prior to screening

• Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) ordiagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptordeficiency or Prader-Willi syndrome)

• Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty ifperformed more than 1 year prior to screening is allowed.

• Known clinically significant gastric emptying abnormality (e.g., severegastroparesis or gastric outlet obstruction)

• History of acute or chronic pancreatitis or clinically significant gallbladderdisease. History of acute pancreatitis caused by gallstones or clinicallysignificant gallbladder disease is allowed if the participant had a cholecystectomyto resolve the problem at least 3 months prior to screening.

• Poorly controlled hypertension at screening

• Any of the following cardiovascular conditions within 3 months prior to screening:Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemicattack; Unstable angina; Hospitalization due to congestive heart failure.

• Have a history of significant active or unstable major depressive disorder (MDD) orother severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, or otherserious mood or anxiety disorder). Participants with MDD or generalized anxietydisorder whose disease state is considered stable within 1 year prior to screeningand expected to remain stable throughout the course of the study, in the opinion ofthe investigator, are allowed provided that they are not receiving prohibitedmedication.

• Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptortriple agonist) within 6 months prior to randomization